Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-24-110907
Filing Date
2024-10-23
Accepted
2024-10-23 17:39:47
Documents
2
Group Members
PARADIGM BIOCAPITAL ADVISORS GP LLCPARADIGM BIOCAPITAL INTERNATIONAL FUND LTD.SENAI ASEFAW, M.D.

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2426437d1_sc13g.htm SC 13G 60557
2 EXHIBIT 1 tm2426437d1_ex1.htm EX-99.1 4974
  Complete submission text file 0001104659-24-110907.txt   67276
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92596 | Film No.: 241390180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017
Business Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017 646-970-2123
Paradigm Biocapital Advisors LP (Filed by) CIK: 0001855655 (see all company filings)

EIN.: 851451055 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G